FIELD: chemistry.
SUBSTANCE: invention relates to a compound of general formula (I), N-oxides thereof on a pyridine ring and pharmaceutically acceptable salts thereof: (I), where: R1 and R2 are different or identical and are independently selected from the group consisting of: linear (C1-C6)-alkyl optionally substituted with one substituent selected from (C3-C7)-cycloalkyl; (C1-C6)-haloalkyl; (C3-C7)-cycloalkyl; R3 is H or represents one or two substituents independently selected from halogen atoms; Z represents a group (CH2)m, where m is 0; A is a phenyl ring optionally substituted by one substituent R4, which is selected from the group consisting of: linear (C1-C6)-alkyl substituted with one morpholinyl; branched (C1-C6)-alkyl optionally substituted by one (C3-C7)-cycloalkyl; (C1-C6)-haloalkyl; (C1-C6)-alkylthio; a halogen atom; and OR7, where R7 is selected from the group consisting of H; (C1-C10)-alkyl optionally substituted by a radical selected from (C3-C7)-cycloalkyl, morpholinyl, phenyl and pyridinyl; and (C1-C10)-alkyl substituted with one OH group; (C1-C6)-haloalkyl; (C3-C7)-cycloalkyl; W is selected from the group consisting of: -NR9SO2R10, -CH2NR13SO2R14, -SO2NR15R16, -NHSO2R17, -OSO2R18, -NHCOR26, where R9, R10, R13, R14, R15, R16, R17, R18, R26 are defined in the claims. Invention also relates to a pharmaceutical composition having PDE4 inhibitory activity based on compounds of formula (I), to an apparatus comprising the composition.
EFFECT: technical result is obtaining novel compounds and pharmaceutical compositions based thereon, that can be used in medicine for the treatment of an allergic disease or respiratory diseases such as atopic dermatitis, urticaria, allergic rhinitis, asthma and COPD.
14 cl, 22 tbl, 37 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS INHIBITORS | 2012 |
|
RU2617401C2 |
DERIVATIVES OF 1-PHENYL-2-PYRIDINYL-ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | 2013 |
|
RU2637945C2 |
1-PHENYL-2-PYRIDINYLALKYL ALCOHOLS DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | 2012 |
|
RU2626956C2 |
BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORγ) AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2789059C2 |
TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | 2014 |
|
RU2659219C2 |
XIA FACTOR INHIBITORS | 2016 |
|
RU2728783C2 |
PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | 2013 |
|
RU2652117C2 |
OXAZINMONOACYLGLYCERIN LIPASE (MAGL) INHIBITORS | 2019 |
|
RU2794334C2 |
SPIRO AMINO COMPOUNDS APPLICABLE FOR TREATING SLEEP DISORDERS AND DRUG ADDICTION | 2010 |
|
RU2562609C2 |
NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATION OF CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | 2015 |
|
RU2684396C2 |
Authors
Dates
2018-05-24—Published
2013-12-04—Filed